MedKoo Cat#: 592611 | Name: Disobutamide

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Disobutamide is a Cardiac Depressant (Anti-Arrhythmic).

Chemical Structure

Disobutamide
Disobutamide
CAS#68284-69-5

Theoretical Analysis

MedKoo Cat#: 592611

Name: Disobutamide

CAS#: 68284-69-5

Chemical Formula: C23H38ClN3O

Exact Mass: 407.2703

Molecular Weight: 408.03

Elemental Analysis: C, 67.70; H, 9.39; Cl, 8.69; N, 10.30; O, 3.92

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
Disobutamide
IUPAC/Chemical Name
1-Piperidinebutanamide, alpha-(2-(bis(1-methylethyl)amino)ethyl)-alpha-(2-chlorophenyl)-
InChi Key
YKFWMDHZMQLWBO-UHFFFAOYSA-N
InChi Code
InChI=1S/C23H38ClN3O/c1-18(2)27(19(3)4)17-13-23(22(25)28,20-10-6-7-11-21(20)24)12-16-26-14-8-5-9-15-26/h6-7,10-11,18-19H,5,8-9,12-17H2,1-4H3,(H2,25,28)
SMILES Code
O=C(N)C(C1=CC=CC=C1Cl)(CCN(C(C)C)C(C)C)CCN2CCCCC2
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.03.00
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 408.03 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Ruben Z, Fuller GC, Knodle SG. Disobutamide-induced cytoplasmic vacuoles in cultured dog coronary artery muscle cells. Arch Toxicol. 1984 Sep;55(3):206-12. PubMed PMID: 6497655. 2: Hjelle JT, Ruben Z. Investigations in intracellular drug storage: localization of disobutamide in lysosomal and nonlysosomal vesicles. Toxicol Appl Pharmacol. 1989 Oct;101(1):70-82. PubMed PMID: 2799819. 3: Ruben Z, Dodd DC, Rorig KJ, Anderson SN. Disobutamide: a model agent for investigating intracellular drug storage. Toxicol Appl Pharmacol. 1989 Jan;97(1):57-71. PubMed PMID: 2464862. 4: Dresel PE, Cameron KD. Effect of disopyramide and disobutamide on conduction in perfused rabbit hearts. Can J Physiol Pharmacol. 1981 Nov;59(11):1192-5. PubMed PMID: 7317843. 5: Ruben Z, Anderson SN, Rorig KJ, Hribar JD, Bible RH Jr. The pH dependence of disobutamide-induced clear cytoplasmic vacuoles in cultured cells. Proc Soc Exp Biol Med. 1985 Oct;180(1):84-91. PubMed PMID: 4034538. 6: Desai BN, Fowler KW, Chorvat RJ, Frederick LG, Hatley FR, Rorig KJ, Garthwaite SM. Synthesis and structure-activity relationships of a new series of antiarrhythmic agents: monobasic derivatives of disobutamide. J Med Chem. 1988 Nov;31(11):2158-64. PubMed PMID: 2846841. 7: Ruben Z, Anderson SN, Fuller GC. The susceptibility of various cultured cells to induction of clear cytoplasmic vacuoles by disobutamide. Toxicol In Vitro. 1990;4(4-5):497-505. PubMed PMID: 20702220. 8: Cook CS, McDonald SJ, Karim A. Importance of pharmacokinetic and physicochemical data in the discovery and development of novel anti-arrhythmic drugs. Xenobiotica. 1993 Nov;23(11):1299-309. PubMed PMID: 8310713. 9: Koizumi H, Watanabe M, Numata H, Sakai T, Morishita H. Species differences in vacuolation of the choroid plexus induced by the piperidine-ring drug disobutamide in the rat, dog, and monkey. Toxicol Appl Pharmacol. 1986 Jun 15;84(1):125-48. PubMed PMID: 3715860. 10: Dohrmann ML, Harrell FE Jr, Strauss HC. The effects of disobutamide on electrophysiologic properties of canine cardiac Purkinje fibers and papillary muscle. J Pharmacol Exp Ther. 1981 Jun;217(3):549-54. PubMed PMID: 7229991. 11: Ruben Z, Anderson SN, Kacew S. Changes in saccharide and phospholipid content associated with drug storage in cultured rabbit aorta muscle cells. Lab Invest. 1991 Apr;64(4):574-84. PubMed PMID: 2016860. 12: Rorig KJ, Ruben Z, Anderson SN. Structural determinants of cationic amphiphilic amines which induce clear cytoplasmic vacuoles in cultured cells. Proc Soc Exp Biol Med. 1987 Feb;184(2):165-71. PubMed PMID: 3809171. 13: Yonan PK, Novotney RL, Woo CM, Prodan KA, Hershenson FM. Synthesis and antiarrhythmic activity of alpha, alpha-bis[(dialkylamino)alkyl]phenylacetamides. J Med Chem. 1980 Oct;23(10):1102-8. PubMed PMID: 7420355. 14: Ruben Z. The pathobiologic significance of intracellular drug storage: clear cytoplasmic vacuoles. Hum Pathol. 1987 Dec;18(12):1197-8. PubMed PMID: 3679197.